{"a":[{"_":"It's crunch time for Karyopharm as company faces potential default next month ","$":{"href":"/pharma/its-crunch-time-karyopharm-it-faces-potential-default-next-month","hreflang":"en"}}]}

Summary

Karyopharm Therapeutics faces potential default within four weeks with depleted cash reserves and Q2 losses of $67 million exceeding current liquid assets. The company's cash runway extends only through the following month.